GACVS Statements on the Safety of Human Papillomavirus Vaccine

Monday, 31st of October 2016

GACVS Statements on the Safety of Human Papillomavirus Vaccine

Excerpt below; full text is at http://www.who.int/immunization/sage/meetings/2016/october/GACVS_Statement_on_the_safety_of_HPV.pdf

“In summary, GACVS was presented with a series of cases of adverse events following the HPV vaccine. Multiple studies have demonstrated no increase in risk of autoimmune diseases, including MS, among girls who received HPV vaccine compared to those who had not. The Committee continues to be reassured by the safety profile of the vaccine, but notes the importance of continued surveillance and epidemiological investigation with an emphasis on the collection of high quality data; such data are essential for interpreting adverse events which occur following vaccination. Allegations of harm from vaccination based on incomplete information can lead to real harm when, as a result, effective vaccines are not used.”